Literature DB >> 24036853

Variation within 3'-UTRs of base excision repair genes and response to therapy in colorectal cancer patients: A potential modulation of microRNAs binding.

Barbara Pardini1, Fabio Rosa, Elisa Barone, Cornelia Di Gaetano, Jana Slyskova, Jan Novotny, Miroslav Levy, Sonia Garritano, Ludmila Vodickova, Tomas Buchler, Federica Gemignani, Stefano Landi, Pavel Vodicka, Alessio Naccarati.   

Abstract

PURPOSE: Colorectal cancer is routinely treated with a 5-fluorouracil (5-FU)-based chemotherapy. 5-FU incorporates into DNA, and the base excision repair (BER) pathway specifically recognizes such damage. We investigated the association of single-nucleotide polymorphisms (SNP) in the 3'-untranslated regions (UTR) of BER genes, and potentially affecting the microRNA (miRNA) binding, on the risk of colorectal cancer, its progression, and prognosis. SNPs in miRNA-binding sites may modulate the posttranscriptional regulation of gene expression operated by miRNAs and explain interindividual variability in BER capacity and response to 5-FU. EXPERIMENTAL
DESIGN: We tested 12 SNPs in the 3'-UTRs of five BER genes for colorectal cancer susceptibility in a case-control study (1,098 cases and 1,459 healthy controls). Subsequently, we analyzed the role of these SNPs on clinical outcomes of patients (866 in the Training set and 232 in the Replication set).
RESULTS: SNPs in the SMUG1 and NEIL2 genes were associated with overall survival. In particular, SMUG1 rs2233921 TT carriers showed increased survival compared with those with GT/GG genotypes [HR, 0.54; 95% confidence interval (CI), 0.36-0.81; P = 0.003] in the Training set and after pooling results from the Replication set. The association was more significant following stratification for 5-FU-based chemotherapy (P = 5.6 × 10(-5)). A reduced expression of the reporter gene for the T allele of rs2233921 was observed when compared with the common G allele by in vitro assay. None of the genotyped BER polymorphisms were associated with colorectal cancer risk.
CONCLUSIONS: We provide the first evidence that variations in miRNA-binding sites in BER genes 3'-UTR may modulate colorectal cancer prognosis and therapy response.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24036853     DOI: 10.1158/1078-0432.CCR-13-0314

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  20 in total

1.  Molecular Biomarkers of Colorectal Cancer and Cancer Disparities: Current Status and Perspective.

Authors:  Upender Manne; Trafina Jadhav; Balananda-Dhurjati Kumar Putcha; Temesgen Samuel; Shivani Soni; Chandrakumar Shanmugam; Esther A Suswam
Journal:  Curr Colorectal Cancer Rep       Date:  2016-09-20

Review 2.  Early detection of colorectal cancer: from conventional methods to novel biomarkers.

Authors:  Nasimeh Vatandoost; Jahanafrooz Ghanbari; Mahboobeh Mojaver; Amir Avan; Majid Ghayour-Mobarhan; Reza Nedaeinia; Rasoul Salehi
Journal:  J Cancer Res Clin Oncol       Date:  2015-02-17       Impact factor: 4.553

3.  Association between miRNA-binding site polymorphisms in double-strand break repair genes and risk of recurrence in patients with squamous cell carcinomas of the non-oropharynx.

Authors:  Lijun Zhu; Erich M Sturgis; Zhongming Lu; Hua Zhang; Peng Wei; Qingyi Wei; Guojun Li
Journal:  Carcinogenesis       Date:  2017-04-01       Impact factor: 4.944

Review 4.  MicroRNAs predict and modulate responses to chemotherapy in colorectal cancer.

Authors:  Xin Yu; Zheng Li; Jun Yu; Matthew T V Chan; William K K Wu
Journal:  Cell Prolif       Date:  2015-07-22       Impact factor: 6.831

Review 5.  MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.

Authors:  Verena Stiegelbauer; Samantha Perakis; Alexander Deutsch; Hui Ling; Armin Gerger; Martin Pichler
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

6.  Polymorphisms in microRNA let-7 binding sites of the HIF1AN and CLDN12 genes can predict pathologic complete response to taxane- and platinum-based neoadjuvant chemotherapy in breast cancer.

Authors:  Yueyao Du; Liheng Zhou; Yanping Lin; Kai Yin; Wenjin Yin; Jinsong Lu
Journal:  Ann Transl Med       Date:  2019-04

7.  A novel c. 204 Ile68Met germline variant in exon 2 of the mutL homolog 1 gene in a colorectal cancer patient.

Authors:  Pavel Vodicka; Fabian Caja; Veronika Vymetalkova; Pavel Prochazka; Ludmila Vodickova; Lucie Schwarzova; Jana Slyskova; Rajiv Kumar; Michaela Schneiderova
Journal:  Oncol Lett       Date:  2014-11-04       Impact factor: 2.967

Review 8.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Authors:  Monica Cipollini; Stefano Landi; Federica Gemignani
Journal:  Pharmgenomics Pers Med       Date:  2014-07-23

9.  Effect of a single nucleotide polymorphism in miR-146a on COX-2 protein expression and lung function in smokers with chronic obstructive pulmonary disease.

Authors:  Ran Wang; Min Li; Sijing Zhou; Daxiong Zeng; Xuan Xu; Rui Xu; Gengyun Sun
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2015-03-04

10.  Double-strand break repair and colorectal cancer: gene variants within 3' UTRs and microRNAs binding as modulators of cancer risk and clinical outcome.

Authors:  Alessio Naccarati; Fabio Rosa; Veronika Vymetalkova; Elisa Barone; Katerina Jiraskova; Cornelia Di Gaetano; Jan Novotny; Miroslav Levy; Ludmila Vodickova; Federica Gemignani; Tomas Buchler; Stefano Landi; Pavel Vodicka; Barbara Pardini
Journal:  Oncotarget       Date:  2016-04-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.